News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs
C. Ola Landgren/X
Apr 14, 2024, 12:56

Carl Ola Landgren: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs

Carl Ola Landgren, Professor of Medicine, Chief of Myeloma Division at University of Miami, shared a post on X:

“I started the EVIDENCE meta-analysis in 2009. After 15 years of work, I will present 4/12 at ODAC: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patient’s access to new drugs?”

Procced to the video.
Source: Carl Ola Landgren/X

cancer Carl Ola Landgren EVIDENCE meta-analysis multiple myeloma Myeloma Myeloma MRD ODAC OncoDaily Oncology oncology drug advisory committe University of Miami
Special Coverage
Blog
Mar 30, 2025, 18:14
Join the Richard and Alice Bucher Emerald Circle and help create a world without pediatric cancers - St. Baldrick's Foundation
Blog
Mar 30, 2025, 18:01
Philippe Spiess: Always an honor to deliver an update in the management of bladder cancer with Tom Flaig
Blog
Mar 30, 2025, 17:46
Thought-provoking trial on localized pancreatic cancer presented by Ethan Agritelley at SSO2025 - Duke Surgical Oncology
Blog
Mar 30, 2025, 17:44
Addressing Gaps in Awareness, Care, and Support for the Early-Age Onset Digestive Cancer Community - European Cancer Organisation
Blog
Mar 30, 2025, 17:34
Olga Kantor: Fantastic presentation by Monika Masanam on MIBC after NST at SSO2025
Blog
Mar 30, 2025, 17:19
Carlos Ayala-Navarro on the immune microenvironment in appendiceal cancers - Moffitt Cancer Center
Blog
Mar 30, 2025, 17:19
Roupen Odabashian: Comparing Research Compensation - Healthcare vs AI
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC
Blog
Mar 30, 2025, 16:43
Highlights from SSO25
Blog
Mar 30, 2025, 16:38
Embracing Palliative Care in Paediatric Oncology from Diagnosis Onwards course is now available on YouTube - SIOPE